Centene Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Centene wird ein jährliches Gewinn- und Umsatzwachstum von 8.9% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.9% betragen.

Wichtige Informationen

8.9%

Wachstumsrate der Gewinne

13.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	4.3%
Zukünftige Eigenkapitalrendite	13.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid

Dec 14

An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued

Nov 11

Is Now The Time To Put Centene (NYSE:CNC) On Your Watchlist?

Oct 26

Centene Q3 2022 Earnings Preview

Oct 24

Centene: Future Growth Will Exceed Market Expectations

Oct 14

Centene: A Chaos Stock

Sep 28

Does Centene (NYSE:CNC) Have A Healthy Balance Sheet?

Sep 20

Centene falls 7%, most since April 2021, on surging volume

Sep 14

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Jul 28

Centene Q2 2022 Earnings Preview

Jul 25

Centene Keeps Overdelivering - But Is Expensive

Jul 11

Is Centene (NYSE:CNC) Using Too Much Debt?

Jun 16

Centene: Solid Q122 Earnings For Health Insurer Helps Make Buy/Hold Case

Apr 28

Centene Has Overdelivered - It Is Time For A 'Hold'

Mar 24

We Think Centene (NYSE:CNC) Can Stay On Top Of Its Debt

Mar 14

Centene: Finally Gets Respect And Is Poised To Profit

Dec 31

Gewinn- und Umsatzwachstumsprognosen

NYSE:CNC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	161,090	3,656	4,127	5,202	10
12/31/2025	155,036	3,236	4,263	4,851	16
12/31/2024	149,618	3,099	1,762	2,962	16
3/31/2024	142,800	2,735	2,603	3,328	N/A
12/31/2023	141,266	2,702	7,254	8,053	N/A
9/30/2023	139,285	2,444	5,451	6,260	N/A
6/30/2023	138,032	2,713	7,651	8,571	N/A
3/31/2023	136,941	1,483	8,392	9,379	N/A
12/31/2022	135,999	1,202	5,257	6,261	N/A
9/30/2022	132,756	2,014	7,493	8,512	N/A
6/30/2022	129,228	1,860	5,985	6,982	N/A
3/31/2022	124,181	1,497	4,348	5,313	N/A
12/31/2021	118,573	1,347	3,295	4,205	N/A
9/30/2021	114,130	736	5,643	6,511	N/A
6/30/2021	111,284	720	2,863	3,757	N/A
3/31/2021	108,158	2,461	4,907	5,786	N/A
12/31/2020	104,280	1,808	4,634	5,503	N/A
9/30/2020	95,764	2,029	1,008	1,871	N/A
6/30/2020	86,523	1,556	1,918	2,724	N/A
3/31/2020	78,105	845	-804	-73	N/A
12/31/2019	70,807	1,321	753	1,483	N/A
9/30/2019	68,385	1,353	784	1,500	N/A
6/30/2019	65,507	1,277	1,498	2,147	N/A
3/31/2019	61,028	1,082	71	704	N/A
12/31/2018	56,688	900	559	1,234	N/A
9/30/2018	52,618	889	1,708	2,318	N/A
6/30/2018	48,655	1,075	1,264	1,867	N/A
3/31/2018	47,201	1,029	1,530	2,087	N/A
12/31/2017	45,810	828	N/A	1,489	N/A
9/30/2017	44,870	853	N/A	2,631	N/A
6/30/2017	43,646	796	N/A	3,016	N/A
3/31/2017	42,468	713	N/A	2,903	N/A
12/31/2016	37,693	562	N/A	1,851	N/A
9/30/2016	32,839	416	N/A	460	N/A
6/30/2016	28,062	360	N/A	40	N/A
3/31/2016	22,948	277	N/A	809	N/A
12/31/2015	21,292	356	N/A	658	N/A
9/30/2015	19,854	350	N/A	827	N/A
6/30/2015	18,548	339	N/A	1,206	N/A
3/31/2015	17,102	298	N/A	1,016	N/A
12/31/2014	15,689	268	N/A	1,223	N/A
9/30/2014	14,134	210	N/A	1,023	N/A
6/30/2014	12,700	179	N/A	713	N/A
3/31/2014	11,475	172	N/A	591	N/A
12/31/2013	10,544	161	N/A	382	N/A
9/30/2013	9,427	209	N/A	183	N/A
6/30/2013	8,932	162	N/A	370	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CNCDas prognostizierte Gewinnwachstum (8.9% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: CNCDie Erträge des Unternehmens (8.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: CNCDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CNCDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CNCDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CNCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.9%).

Centene Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Centene Corporation Updates Earnings Guidance for the Year 2024

Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024

Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Recent updates

A Piece Of The Puzzle Missing From Centene Corporation's (NYSE:CNC) Share Price

Returns At Centene (NYSE:CNC) Appear To Be Weighed Down

Centene Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well

Centene Corporation Still An Opportunity With An A-Grade Valuation

Centene Corporation, Annual General Meeting, May 14, 2024

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Centene Corporation to Report Q1, 2024 Results on Apr 26, 2024

Market Still Lacking Some Conviction On Centene Corporation (NYSE:CNC)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024

Centene Corporation Announces Appointment of Michael A. Carson as President and Chief Executive Officer of Its Medicare Business

Centene: Stay Defensive Amid Economic Uncertainty With This Low-Beta Bargain

Is Centene (NYSE:CNC) Using Too Much Debt?

Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC).

Centene Corporation to Report Fiscal Year 2023 Results on Feb 06, 2024

Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024

Centene: Overlooked Healthcare Giant

Centene Corporation Announces the Appointment of Susan Smith as Chief Operating Officer, Effective January 1, 2024

Does Centene (NYSE:CNC) Deserve A Spot On Your Watchlist?

Centene: Solid Performance With Positive Outlook, But Limited Upside Potential

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Centene Corporation Names Wade Rakes as Chief Growth Officer

These 4 Measures Indicate That Centene (NYSE:CNC) Is Using Debt Reasonably Well

Decoding Centene: Why I Think It's Undervalued

Centene Corporation to Report Q3, 2023 Results on Oct 24, 2023

Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion.

If EPS Growth Is Important To You, Centene (NYSE:CNC) Presents An Opportunity

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Centene: Results Impress But Buyers Aren't Swarming Yet

Centene (NYSE:CNC) Has A Pretty Healthy Balance Sheet

Centene Corporation to Report Q2, 2023 Results on Jul 28, 2023

New Mountain Capital, L.L.C. acquired Apixio, Inc. from Centene Corporation.

Centene Corporation Appoints T. Susko as Its Senior Vice President and Chief Communications Officer

Centene Corporation Announces Resignation of James E. Murray as Chief Operating Officer

New Mountain Capital, L.L.C. agreed to acquire Apixio, Inc. from Centene Corporation (NYSE : CNC).

Centene to Divest AI Platform Apixio

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Centene (NYSE:CNC) Seems To Use Debt Quite Sensibly

CEO & Director recently bought US$1.9m worth of stock

Independent Director recently bought US$503k worth of stock

Centene Corporation Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings: EPS misses analyst expectations

Centene Non-GAAP EPS of $0.86 beats by $0.02, revenue of $35.56B beats by $190M

With EPS Growth And More, Centene (NYSE:CNC) Makes An Interesting Case

Centene (NYSE:CNC) Seems To Use Debt Rather Sparingly

Centene: Once Again, With Quality, Now A 'Buy'

Centene Corporation to Report Fiscal Year 2022 Results on Feb 07, 2023

Centene Corporation Announces Management Changes

Centene appoints new leadership; Ken Fasola President of Centene, Dave Thomas CEO of Medicaid

Vivalto Santé SA completed the acquisition of Torrejon Salud, S.A. from Centene Corporation (NYSE:CNC).

Vivalto Santé SA completed the acquisition of Ribera Salud, S.A from Centene Corporation (NYSE:CNC).

Centene Corporation Appoints Monte Ford to Board of Directors

High number of new directors

An Intrinsic Calculation For Centene Corporation (NYSE:CNC) Suggests It's 50% Undervalued

Insider notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Centene Corporation Provides Earnings Guidance for the Full Year 2022

Is Now The Time To Put Centene (NYSE:CNC) On Your Watchlist?

Centene Q3 2022 Earnings Preview

Centene: Future Growth Will Exceed Market Expectations

Centene Corporation to Report Q3, 2022 Results on Oct 25, 2022

Centene: A Chaos Stock

Does Centene (NYSE:CNC) Have A Healthy Balance Sheet?

Centene falls 7%, most since April 2021, on surging volume